After mega-round investment, ADC Therapeutics cans PhI trial in HER2
After raising a $200 million mega-round just months ago, Swiss drugmaker ADC Therapeutics is axing one of its programs due to toxicity issues.
The cut drug program, called ADCT-502, is one of the company’s several antibody-drug conjugate (ADC) candidates in development for solid and blood cancers. The 502 drug was being tested in a Phase I trial with patients who have HER2-positive cancers. But as the company’s CMO Jay Feingold explains it, the HER-2 targeted ADC wasn’t working well enough in low doses, which is a problem considering the side effects.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.